It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are...

Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.

IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.